Technetium medronate
As of the edition of 20 October 2026, Technetium medronate is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Technetium Tc 99M Mpi Mdp
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 1 region
- Holder of the most recent approval
- Jubilant DraxImage; 4 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 1 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Draximage | Applicant | 2004 to now |
| Cardinal Health 414 Llc Cardinal Health Nuclear Pharmacy | Acquired holder | 2017 to now |
| Jubilant DraxImage | Acquired holder | 2020 to now |
| SUN Pharmaceutical Industries | Acquired holder | 2020 to now |
| GE Healthcare | Later holder | |
| Merck & Co. | Earlier holder |